UK & EU Commercial launch of SpydrBlade™ Flex

Creo Medical Group plc

("Creo" the "Company" or the "Group")

UK & EU Commercial launch of SpydrBlade™ Flex

A world Leading NHS Endoscopy unit first commercial customer of SpydrBlade Flex for Lower GI colorectal resections

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces the commercial launch and first customer of its SpydrBlade Flex1 technology, a unique multi-modal endoscopic device designed for precision and adaptability in endoscopic procedures, in the UK and Europe.

Following extensive pre-launch global clinical activity, this first customer marks the UK & EU commercial launch of SpydrBlade Flex, and is being pioneered in St Mark's Hospital in NW London, one of the UK's leading Endoscopy Units and recognised as a world centre of excellence by the WEO (World Endoscopy Organisation). St Mark's Hospital is also an established and regular user of Creo's Speedboat UltraSlim.

Creo will be ramping up the full commercial launch via its core sales channels in the UK and the EU as well as other international territories, including the US, once local regulatory approvals have been received.

SpydrBlade Flex will be showcased amongst the latest endoscopy technology at the upcoming ESGE (European Society of Gastrointestinal Endoscopy) Days 2025 conference in Barcelona in April.

Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted to announce the commercial launch of our SpydrBlade Flex product in the UK and across Europe and it is fitting that the first commercial customer is such a recognised centre as St Marks. SpydrBlade really is one of the most advanced surgical tools and again, Creo have pioneered the introduction of this technology into the tiny footprint of a flexible endoscopic instrument. Speedboat UltraSlim alongside SpydrBlade Flex will enhance the care of patients with a wide range of conditions ranging from cancers to swallowing disorders, as well as their increasing use in the rapidly growing treatment of Barriatric conditions.

"Both products will continue to help move the point of care from Surgery and the operating theatre to the endoscopy room allowing us to further reduce surgical waiting lists not only in the NHS, but globally. We expect to see further commercial traction as more people adopt our new technology, and following further regulatory approvals, including the FDA clearance to allow our commercial launch in the US."

Above: The SpydrBlade Flex "the most versatile dissection tool in flexible endoscopy"

Notes

1https://www.creomedical.com/en/kamaptive-technology/spydrblade-flex

For further information please contact: 

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com